Tirzepatide clinical trial results explained
The SURMOUNT trials in plain language — the dose-response 20.9% result, the head-to-head win over semaglutide, and how to turn efficacy into cost-per-result.
SURMOUNT-1: the trial that defined tirzepatide for weight loss
Tirzepatide's weight-management evidence base is the SURMOUNT program — phase 3 randomized trials of the FDA-approved brand product (Zepbound). The pivotal SURMOUNT-1 trial, published in 2022, enrolled 2,539 adults with obesity or overweight-plus-comorbidity, without diabetes, over 72 weeks. Mean weight loss was dose-dependent: about 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg, versus 3.1% on placebo. The share of participants losing at least 5% ranged from roughly 85% to 91% across doses, and a striking proportion — over half at the 15 mg dose — lost 20% or more, a threshold previously associated mainly with bariatric surgery.
The full SURMOUNT program
Later trials extended the picture across populations. SURMOUNT-2 studied adults who also had type 2 diabetes and found smaller but still substantial average loss (~14.7% to 15.7% at the higher doses), consistent with the pattern that people with diabetes tend to lose somewhat less. SURMOUNT-3 added tirzepatide after an intensive lifestyle lead-in and produced a further ~18.4% on top of the run-in loss. SURMOUNT-4 was a withdrawal trial that showed continued treatment maintained and extended loss, while switching to placebo produced substantial regain. Together they establish tirzepatide as among the most effective pharmacological weight-management agents studied to date.
| Trial | Population | Duration | Mean weight loss (top dose) |
|---|---|---|---|
| SURMOUNT-1 | Obesity, no diabetes | 72 weeks | ~20.9% (15 mg) |
| SURMOUNT-2 | Obesity + type 2 diabetes | 72 weeks | ~15.7% |
| SURMOUNT-3 | After lifestyle lead-in | 72 weeks | ~18.4% additional |
| SURMOUNT-4 | Withdrawal design | 88 weeks | ~26% (continued) |
| SURMOUNT-5 | Head-to-head vs semaglutide | 72 weeks | ~20.2% |
The head-to-head result: SURMOUNT-5
The most decisive comparison arrived in 2025. SURMOUNT-5 randomized adults directly to tirzepatide or semaglutide 2.4 mg — the first head-to-head of the two leading agents. Tirzepatide produced significantly greater average weight loss: about 20.2% versus 13.7% over 72 weeks. That roughly 6.5-percentage-point gap is the strongest evidence that, on average, tirzepatide's dual mechanism delivers more weight loss than semaglutide's single mechanism — though semaglutide remains highly effective, better-studied over long horizons, and usually cheaper in the compounded market.
Turning efficacy into cost-per-result
Efficacy becomes a buying decision when you divide by price. Using July 2026 flat-rate compounded pricing (~$186/month, ~$2,232/year) against SURMOUNT-1's ~20.9% average, the implied cost per percentage point of expected weight loss is far lower than at brand retail — though the compounded product is not FDA-approved and its real-world performance is not established by these brand trials.
| Scenario (annual) | Cost/year | Trial-avg % lost | Cost per 1% (illustrative) |
|---|---|---|---|
| Flat-rate compounded ($186/mo) | $2,232 | ~20.9% | ~$107 |
| Dose-tiered (~$300/mo avg) | ~$3,600 | ~20.9% | ~$172 |
| Brand Zepbound retail (~$1,086/mo) | ~$13,032 | ~20.9% | ~$624 |
Three honest caveats: trial averages hide wide individual variation; SURMOUNT studied the brand, so applying these percentages to a compounded product is an assumption, not a finding; and weight loss reverses substantially after stopping, so the durable comparison is annual cost of continued therapy.
What real-world data add to the trials
Trial averages set expectations, but real-world evidence broadly supports them while adding nuance. Large retrospective cohorts of adults on tirzepatide find weight loss in the high-teens percent range at about a year, close to SURMOUNT-1, though real-world adherence is lower and dropout higher, which pulls the full-population average down. The gap between efficacy and effectiveness is mostly a story about adherence: people who stay on the medication and titrate to an effective dose track the trial numbers, while those who stop early for side effects, cost, or access see less. This is why the support wrapped around the molecule matters — a program that keeps you supported through titration and keeps pricing predictable so cost never forces an abrupt stop is part of what determines whether you get a trial-like outcome, not a luxury on top of the medication. It is also why our rubric weights bundled clinical support alongside price when ranking tirzepatide programs.
Frequently asked questions
How much weight did people lose on tirzepatide in trials?
In SURMOUNT-1 (72 weeks), mean weight loss was ~15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) versus 3.1% on placebo, with roughly 91% of the 15 mg group losing at least 5%. These are figures for the FDA-approved brand product; individual results vary.
Is tirzepatide more effective than semaglutide?
In the head-to-head SURMOUNT-5 trial, tirzepatide produced greater average loss than semaglutide (20.2% vs 13.7% over 72 weeks). Semaglutide remains highly effective and often cheaper in the compounded market.
Do compounded tirzepatide products match trial results?
There is no trial base for compounded tirzepatide specifically. SURMOUNT results describe the FDA-approved brand product. Compounded products are not FDA-approved and their performance is not established by these trials.
What is the cost per percent of weight loss?
Dividing July 2026 annual cost by SURMOUNT-1's ~20.9% average gives roughly $107 per percentage point on a $186/mo flat plan versus ~$624 at brand retail — an illustrative pricing comparison, not a clinical claim.
References
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022.
- Garvey WT, et al. Tirzepatide in obesity with type 2 diabetes (SURMOUNT-2). Lancet. 2023.
- Aronne LJ, et al. Continued tirzepatide vs placebo (SURMOUNT-4). JAMA. 2024.
- Aronne LJ, et al. Tirzepatide vs semaglutide (SURMOUNT-5). N Engl J Med. 2025.
- Eli Lilly. Zepbound (tirzepatide) Prescribing Information.
Clinical figures from published trials and FDA labeling; pricing from provider-advertised rates checked July 2026 and subject to change. Educational, not medical or financial advice.